This is a clinical trial in which 40 participants with schizophrenia will be randomized to 15 days of treatment with cariprazine (CAR) or brexpiprazole (BREX) in a single-blind manner. [11C]PHNO PET scans will be obtained before treatment and after 1 day and 15 days of treatment to examine the effects of antipsychotic medications on the dopamine-3 receptor (D3R). The overall objectives of the current study are to: 1) measure the acute binding of CAR/BREX to the D3R; 2) measure D3R availability for evidence of upregulation following subchronic administration of CAR/BREX in the same set of patients; 3) examine relationships between subchronic binding of CAR/BREX to, and upregulation of, the D3R vs. D2R and changes in positive symptoms, negative symptoms, and cognitive deficits. Relationships between subchronic binding of CAR/BREX and EPS will be explored.
Inclusion Criteria:
Exclusion Criteria:
ragy.girgis@nyspi.columbia.edu646-774-5553
Non clinical personnel and PET data analysts
Cariprazine 1mg daily for 15 days
Cariprazine 2mg daily for 15 days
Cariprazine 3mg daily for 15 days
Cariprazine 4mg daily for 15 days
Brexpiprazole 1mg daily for 15 days
Brexpiprazole 2mg daily for 15 days
Brexpiprazole 3mg daily for 15 days
Brexpiprazole 4mg daily for 15 days
PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia
Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia
Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia